- In the phase 3 RESONATE study, patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) receiving ibrutinib experienced notable improvements in hematologic function and disease-related symptoms vs those receiving ofatumumab.
Why this matters
- According to patient-reported outcomes (PRO), the emotional well-being of patients with CLL is generally lower than that reported by patients with other malignancies.
- Analysis of PRO parameters in the RESONATE study of 391 patients with R/R CLL/SLL receiving ibrutinib (n=195) or ofatumumab (n=196).
- Median number of prior therapies:
- Ibrutinib group: 3 (range, 1-12).
- Ofatumumab group: 2 (range, 1-13).
- Funding: Pharmacyclics LLC, an AbbVie Company.
- Significantly greater proportion of patients with sustained hematologic improvement with ibrutinib vs with ofatumumab:
- Improved platelets: 82% vs 22% (P<.0001>
- Improved neutrophils: 68% vs 32% (P=.011).
- Improved hemoglobin: 69% vs 37% (P<.0001>
- Improvement in any cytopenia: 79% vs 43% (P<.0001>
- Weight loss: 100% vs 87%.
- Fatigue: 79% vs 64%.
- Night sweats: 89% vs 77%.
- Abdominal pain/discomfort: 96% vs 75%.
- Anorexia: 100% vs 64%.
- Patient-reported data.